<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5569A12-0A1B-4474-B608-84BB0C44B3A7"><gtr:id>F5569A12-0A1B-4474-B608-84BB0C44B3A7</gtr:id><gtr:name>University of Minnesota</gtr:name><gtr:address><gtr:line1>127 Vincent Hall</gtr:line1><gtr:line2>206 Church St. S.E</gtr:line2><gtr:line4>Minneapolis</gtr:line4><gtr:line5>MN 55455</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5569A12-0A1B-4474-B608-84BB0C44B3A7"><gtr:id>F5569A12-0A1B-4474-B608-84BB0C44B3A7</gtr:id><gtr:name>University of Minnesota</gtr:name><gtr:address><gtr:line1>127 Vincent Hall</gtr:line1><gtr:line2>206 Church St. S.E</gtr:line2><gtr:line4>Minneapolis</gtr:line4><gtr:line5>MN 55455</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4CFEE661-9281-4E12-B253-109123EF97A4"><gtr:id>4CFEE661-9281-4E12-B253-109123EF97A4</gtr:id><gtr:firstName>Ann</gtr:firstName><gtr:otherNames>Sarah</gtr:otherNames><gtr:surname>Walker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2974F5C5-0680-4FF1-B890-F2D890748449"><gtr:id>2974F5C5-0680-4FF1-B890-F2D890748449</gtr:id><gtr:firstName>Ibrahim</gtr:firstName><gtr:surname>Abubakar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/168CFD16-EA26-4A8A-B3E6-5E11BD817F3E"><gtr:id>168CFD16-EA26-4A8A-B3E6-5E11BD817F3E</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Tyre</gtr:otherNames><gtr:surname>Dunn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12023%2F22"><gtr:id>8B359B8E-2C51-45F1-8844-F65748E112A9</gtr:id><gtr:title>Other infectious diseases of global public health significance</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12023/22</gtr:grantReference><gtr:abstractText>Antibiotic resistance, viral hepatitis and infections which can cause a global epidemic such as influenza, place major burdens on human health. Our research focusses on the following:
1) Antibiotic resistance. One of objectives is to see if we can treat common infections such as pneumonia with shorter courses of antibiotics. Another is to see if using two antibiotics for a short time might improve outcomes when people have blood infections. Last, whether we can find new uses for older antibiotics that are no longer widely used but might be very effective for resistant bugs that have become more common in hospitals;
2) Hepatitis C. There are now several very well tolerated oral drugs which cure &amp;gt;90% of patients with Hepatitis C with just 12-24 weeks of treatment. However, they are very expensive and not widely available. We are planning a study to see if people can be cured with even shorter treatment courses of between 4-6 weeks. 
3) Infections that ?go global?. The 2009 ?swine flu? outbreak, only 6 years after SARS, reminded us of how important it is to prepare for global epidemics. We are part of two international influenza studies trying to understand how influenza changes over time and what factors predict who will do badly if they get flu. We are now trialling a new treatment (FLU-IVIG) for those severely ill, hospitalised with influenza.</gtr:abstractText><gtr:technicalSummary>Antimicrobial resistance, viral hepatitis and infections with pandemic potential place a major burden on human health. Our research focusses on:
1) Antibiotic-resistance ? which increases morbidity/mortality for the individual and has huge public health implications. Our research aims to i) demonstrate in well-conducted trials that narrower spectrum antibiotics do not lead to poorer clinical outcomes; ii) assess the role of shorter antibiotic courses as a mechanism to reduce antibiotic selection pressure (CAP-IT) and the utility of short course dual antibiotics to effect more rapid bacterial kill in bacterial sepsis syndromes with high morbidity and mortality (ARREST);
iii) investigate the role of old, now rarely used narrower spectrum antibiotics and/or repurpose existing narrower spectrum antibiotics as alternatives to broad spectrum antibiotics; iv) investigate novel point-of-care biomarkers to more clearly distinguish bacterial from viral infection and avoid using antibiotics inappropriately.
2) Viral hepatitides, in particular hepatitis C where a number of very potent, low toxicity oral direct acting antivirals (DAA) are able to cure &amp;gt;90% of patients with just 12-24 weeks of treatment. This offers the chance of global elimination because treatment could be shifted to the community and the brevity of the treatment means hard-to-reach populations could be treated successfully. There is a major caveat, in that these DAA are very expensive and hence not universally available, and moreover, do not prevent re-infection. We aim to explore a strategy of treating immediately vs. deferring in those with minimal liver disease to better understand the clinical benefits of treatment; a second study exploring the utility of even shorter DAA courses is also planned.
3) Emergent infections with pandemic potential. The 2009 influenza pandemic, only 6 years after the SARS coronavirus outbreak in 2003, served to illustrate the importance of a world-wide rapid-response infrastructure ready for future pandemics. MRC CTU as part of the INSIGHT network, established two observational studies in influenza, in the hospital (FLU003 Plus) and out-patient (FLU002 Plus) settings in direct response to this pandemic. These studies, along with the genetic substudy (INSIGHT-004) aim to inform on the longitudinal changes in clinical presentation of differing influenza strains, understand influenza strain drift/shift, antiviral resistance and the genetics that underpin poorer outcomes. We are now trialling a passive immunotherapy (FLU-IVIG) for those severely ill and hospitalised with influenza. This represents a novel treatment, which if found to be effective is likely to be developed into a commercialised polyclonal antibody product.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>404000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sussex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Brighton and Sussex Medical School</gtr:department><gtr:description>Brighton and Sussex Medical School</gtr:description><gtr:id>B7CB6741-C353-4CC1-8775-68ACF9516125</gtr:id><gtr:impact>Multidiscplinary, including clinical medicine, statistics, trial management, laboratory management.</gtr:impact><gtr:outcomeId>56d55ebdc43479.53896265-1</gtr:outcomeId><gtr:partnerContribution>Dr Martin Llewelyn is one of the clinicians working with the MRC CTU at UCL in this field, bringing additional expertise in clinical medicine.</gtr:partnerContribution><gtr:piContribution>MRC CTU at UCL is collaborating on developing proposals for trials in the fields of antibiotic treatment/antimicrobial resistance in adults</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Imperial College, London</gtr:description><gtr:id>4B632EFA-2F38-40D7-8DB2-1865675E754D</gtr:id><gtr:impact>Multi-disciplinary, comprising clinical medicine, statistics, clinical trials, laboratory management.
Grant awarded for first randomised trial from NIHR EME 2015. 
GCRF funding awarded to set up a research collaboration with the Hospital for Tropical Diseases, Ho Chi Minh City, in 2016.</gtr:impact><gtr:outcomeId>56d55b99499f09.35042981-1</gtr:outcomeId><gtr:partnerContribution>Dr Cooke is the Chief Investigator of one actively recruiting trial (STOP-HCV-1) that is being run from MRC CTU at UCL, and is also the Principal Investigator on other funded and submitted proposals for trials in Hepatitis C in Vietnam.</gtr:partnerContribution><gtr:piContribution>The MRC CTU at UCL is collaborating with Dr Graham Cooke on new randomised trials of direct acting antivirals for Hepatitis C infection.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Medicine</gtr:department><gtr:description>Oxford University</gtr:description><gtr:id>F33EB8B8-48B4-40EA-9B34-398B15DB4007</gtr:id><gtr:impact>Multidiscplinary, including clinical medicine, statistics, trial management, laboratory science and management.

The ARREST trial was funded by the NIHR HTA in 2012
The STOP-HCV-1 trial was funded by NIHR EME in 2015.</gtr:impact><gtr:outcomeId>56d55cbdae0137.96672695-1</gtr:outcomeId><gtr:partnerContribution>Prof Guy Thwaites is the Chief Investigator for the ARREST trial of adjunctive rifampicin: Prof Ellie Barnes leads the STOP-HCV Consortium and is thus a key collaborator on new randomised trials in Hepatitis C.</gtr:partnerContribution><gtr:piContribution>MRC CTU at UCL is collaborating on trials in the fields of antibiotic treatment/antimicrobial resistance (Prof Guy Thwaites) and Hepatitis C (Prof Ellie Barnes).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Minnesota</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Division of Biostatistics/CCBR</gtr:department><gtr:description>International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)</gtr:description><gtr:id>FB6ED32B-2415-417A-BDFF-B7CD89A1E819</gtr:id><gtr:impact>none yet for FLU-IVIG, the study is still enrolling.</gtr:impact><gtr:outcomeId>58c53947487153.42126965-1</gtr:outcomeId><gtr:partnerContribution>Partners in this international RCT, are located in other parts of the EU (Denmark and Spain), Australia, Argentina, Thailand and the USA. Four international Coordinating have sites in these locations under their jurisdiction and are responsible for ensuring the study enrols in a timely manner and in accordance with ICH-GCP. the current enrolment is 150 of the planned 320 participants.The study is sponsored by the University of Minnesota, and funded by National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-1504, US.</gtr:partnerContribution><gtr:piContribution>We have a leadership role (Dr Sarah Pett is one of the global co-Chairs) in the FLU-IVIG (INSIGHT 006) intervention study, and as such have contributed to the development of the protocol (intellectual input) exploring in a randomised, double-blind placebo controlled study, the clinical benefits of hyper-immune (enriched for influenza antibodies) immunoglobulin for patients hospitalised with influenza. We have 4 sites in the UK and 5 sites in Greece under our jurisdiction and we coordinate all aspects of the study at these 9 sites including training, day-to-day management. Completion of the study is expected after the 2017-2018 northern hemisphere influenza season.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>St George's University of London</gtr:description><gtr:id>EC41DED5-87AA-4900-B9A4-1929B4809984</gtr:id><gtr:impact>Multidiscplinary, including clinical medicine, statistics, trial management, laboratory management.

The CAP-IT trial was funded by the NIHR HTA.</gtr:impact><gtr:outcomeId>56d55d656044f5.91597064-1</gtr:outcomeId><gtr:partnerContribution>Prof Mike Sharland is the Chief Investigator for the CAP-IT trial investigating high vs low dose, and short-course vs long-course, amoxicillin for paediatric community acquired pneumonia.</gtr:partnerContribution><gtr:piContribution>MRC CTU at UCL is collaborating on randomised trials in the fields of antibiotic treatment/antimicrobial resistance in children.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1416142</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR HTA (ARREST)</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>10/104/25</gtr:fundingRef><gtr:id>F7C6F161-786D-4AB2-91FA-E05E2E90C270</gtr:id><gtr:outcomeId>56d5628e0e0c19.51989102</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>440453</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GCRF (SEARCH)</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/P025064/1</gtr:fundingRef><gtr:id>19812360-0D6E-4A8D-8D7B-083317A320EA</gtr:id><gtr:outcomeId>58c548551cb674.38688774</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2532730</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR HTA (CAP-IT)</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>13/88/11</gtr:fundingRef><gtr:id>4C547166-FC63-45F9-9376-1B48484A5AEA</gtr:id><gtr:outcomeId>56d5979e5891d8.26247030</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1691167</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR EME (STOP-HCV-1)</gtr:description><gtr:end>2020-01-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>14/02/17</gtr:fundingRef><gtr:id>26D6B58B-BE22-4050-B8F5-32BC44D58664</gtr:id><gtr:outcomeId>56d5b1c2ac61c1.43671506</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Short-course direct acting antivirals against Hepatitis C infection, where the duration of treatment is determined by the baseline Hepatitis C virus level in the blood. 8-12 weeks of direct acting antivirals are licenced to cure Hepatitis C, but the optimal duration of treatment is unknown and likely depends on key patient factors (stratified or personalised medicine). NIHR EME have funded a RCT (n=408) in the UK to test whether treatment duration can be successfully stratified/personalised based on Hepatitis C virus levels in the blood.</gtr:description><gtr:id>47B6F635-45C6-4FA4-B019-A75CD278188F</gtr:id><gtr:impact>None.</gtr:impact><gtr:outcomeId>56d5c05c6c8789.79617336</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Short-course direct acting antivirals for Hepatitis C</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Adjunctive rifampicin in addition to standard antibiotic treatment for bacteraemia caused by Staphylococcus aureus. Rifampicin is licenced for this indication, but there are no data as to whether including it in combination has any benefits in terms of mortality and morbidity and there is considerable variation in clinical practice. NIHR HTA have funded a large (n=770) RCT in the UK to address this question.</gtr:description><gtr:id>BC762D38-D6B5-4E8A-AFA1-3D5D31D8207D</gtr:id><gtr:impact>Developing the scientific concept behind and running this trial has necessitated pulling together a network of committed microbiology/infectious disease specialists across the UK. This group is highly committed to developing more randomised trials to address pressing questions antibiotic treatment, particularly to address the pressing question of antimicrobial resistance.</gtr:impact><gtr:outcomeId>56d5be8a6eb324.10802744</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ARREST - rifampicin</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>High-dose vs low-dose and short-course vs long-course amoxicillin for paediatric community acquired pneumonia.

Amoxicillin is licenced for this indication, but different doses are used in different countries (both across Europe and worldwide) and there are no data on the optimal duration of treatment. Shorter treatment could reduce pressure for the development of antimicrobial resistance, and reduce side-effects. NIHR HTA have funded a large RCT in the UK to address this question.</gtr:description><gtr:id>CE0D1FBE-9863-4D4E-9CD4-5DCE03C82D60</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>56d5bf8740a0b2.65100239</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>High-dose and/or long-course amoxycillin</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>53FD4FC1-8B98-4927-9630-91666848BF40</gtr:id><gtr:title>INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f478c468a1f3d730340b9c725a3e8fbf"><gtr:id>f478c468a1f3d730340b9c725a3e8fbf</gtr:id><gtr:otherNames>INSIGHT FLU005 IVIG Pilot Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>56dc9a9aba87b0.08760221</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01AA2A0E-8CE3-4991-BACA-D630A1DB036A</gtr:id><gtr:title>Evidence for human transmission of amyloid-? pathology and cerebral amyloid angiopathy.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46f5fbd4a8def22591a116738bda4515"><gtr:id>46f5fbd4a8def22591a116738bda4515</gtr:id><gtr:otherNames>Jaunmuktane Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>56d559a1c60217.89979212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FF55A2B-9A5D-44E6-9838-BF80965ACED0</gtr:id><gtr:title>Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbee40658e79cab5d825627f276ab357"><gtr:id>cbee40658e79cab5d825627f276ab357</gtr:id><gtr:otherNames>Mead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>56d559a2d3e305.51032018</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31910772-CB8C-43D8-AA6F-662D79F44EED</gtr:id><gtr:title>Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b894d617f13738cd8d0c6f606c985d7"><gtr:id>5b894d617f13738cd8d0c6f606c985d7</gtr:id><gtr:otherNames>Peterson RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>5a9d5d9a0275d6.00010885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA6D8263-D1CF-46AE-830E-58AD733C7706</gtr:id><gtr:title>Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47e4f6b1c8b4cf419768228fb65c77c4"><gtr:id>47e4f6b1c8b4cf419768228fb65c77c4</gtr:id><gtr:otherNames>Thwaites GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5a3cddc138f8e7.19263292</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12023/22</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>